Neurocrine Biosciences, Inc., a leading neuroscience-focused biopharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) has accepted its supplemental New Drug Application...
Catalyst Pharmaceuticals, Inc. ("Catalyst"), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare diseases, announced that...
Verona Pharma plc, announces positive results of its Phase 3 ENHANCE-1 trial evaluating nebulized ensifentrine for the maintenance treatment of chronic obstructive pulmonary disease...
MimiVax is pleased to announce the published manuscript of the now completed Phase IIa study of SurVaxM, a cancer vaccine, in newly diagnosed glioblastoma...
